Given its ability to reduce metastatic spread in in vivo models by inhibiting L-selectin mediated adhesion and interfering with P-selectin mediated aggregation of platelets on tumor cells [19, 59], heparin has been explored for its potential as an anti-metastatic therapeutic. Here, SELP is linked to neoplasm.